⭐We interviewed Dr Amit Mahipal on a recent study of atezolizumab + bevacizumab as a first-line treatment for HCC. 👉 Dr. Mahipal describes the benefits of the combination, and reviews the differences between Child-Pugh and ALBI scores for patients: buff.ly/3WQRZ2U

💉 Standard treatment for esophageal squamous cell carcinoma includes neoadjuvant chemoradiation and esophagectomy, but the surgery is often linked to complications. 🔎 The preSINO trial analyzed the efficacy of active surveillance after chemoradiation: buff.ly/4dXBglv

❓ What's the difference between Child-Pugh and ALBI scores? 👉 Dr Amit Mahipal discusses the differing factors utilized by each test, as well as which one may better predict mortality or benefit: buff.ly/3WQRZ2U

❗️Tempest Therapeutics announced that a U.S. FDA end-of-phase 2 meeting garnered positive feedback for #amezalpat + atezolizumab and bevacizumab for 1L unresectable or metastatic HCC. 🔎 The study will compare the combination with atezolizumab and bevacizumab: buff.ly/3YPCZVE

🚨 #ICYMI: The U.S. FDA has accepted a Biologics License Application for nivolumab (Opdivo) plus ipilimumab (Yervoy) as a first-line treatment for unresectable HCC. 👉 The decision was based on results from the phase 3 CheckMate-9DW study: buff.ly/4dMlKIQ

⭐ #ICYMI, Dan Kaufman, professor of medicine at UC San Diego, discusses TGF-β and how it is linked to the development of hepatocellular carcinoma. 👉 Learn more about how TGF-β inhibition works with anti-HCC CARs to promote anti-tumor activity: buff.ly/4cSOr6a

❓ What's the difference between Child-Pugh and ALBI scores? 👉 Dr Amit Mahipal discusses the differing factors utilized by each test, as well as which one may better predict mortality or benefit in his discussion on atezolizumab with bevacizumab for HCC: buff.ly/3WQRZ2U

🔎 As monomodal data has shown a lack of proficiency in understanding diverse presentations of HER2+ gastric cancer, a recent study used a multimodal analytic approach to predict treatment responses to anti-HER2 or anti-HER2 combined immunotherapy: buff.ly/3TyJMzJ

📋 While research has shown an increase in GISTs after GIST-specific histology coding, there is a lack of knowledge on updated data & trends. 🔬 A study from Christian Álvarez and colleagues sought to determine the epidemiology of GISTs across major organ sites: buff.ly/4g7tM11

💊 Treatment for ESCC consists of neoadjuvant chemoradiation and esophagectomy, but the surgery is linked to complications. 🔬 The preSINO trial analyzed the efficacy of active surveillance through clinical response evaluations after chemoradiation: buff.ly/4dXBglv

💊 Can adding oxaliplatin to doublet chemotherapy with fluoropyrimidine benefit older patients with unresectable metastatic colorectal cancer? 🔬 New research has examined the potential triplet therapy: buff.ly/47dEkHS

🏥 What happens when #endoscopists, #EUS imaging, and multimodal AI all work together to #diagnose solid #pancreatic #tumors? 💡 Read more about the latest research here: buff.ly/4cVCSLt

Which do you prefer in treating HCC: upfront surgical resection or neoadjuvant chemotherapy? ❓ buff.ly/3AXDC5K

📣 #ESMO24 content coming your way 💉 #Firstline #triplettherapy in treatment-naive patients with #KRAS #G12C #mutated #mCRC demonstrated an acceptable #safety profile 🧠 Learn more: buff.ly/3zgpILk

✨ "Unprecedented" 5-year #survival benefit with #STRIDE regimen in #unresectable #HCC ✨ 🔎 Check out the #ESMO2024 data here: buff.ly/3TqrWi0

❄️ POLAR trial findings presented at #ESMO2024 lay the groundwork for combining #immunotherapy and #PARPinhibitors in #metastatic #pancreatic #cancer ❄️ Read more: buff.ly/4emQ0ua

The opening session of #ESMO24 has officially kicked off the conference with ESMO - Eur. Oncology president Andrés Cervantes!

Dr. Ryan Corcoran of Mass General Cancer Center talks KRAS inibition, molecular subtypes, and the biology of #colorectal cancer during his mCRC #ESMO24 presentation.

🧫 The first #randomized study to use #liquidbiopsy #cetuximab rechallenge may offer a much-needed #alternative in #metastatic #colorectalcancer More here #ESMO24 👉 buff.ly/3zcJ301

🧬 #Novel #KRAS #mutation #degrader shows ✔️ positive #safety profile and #antitumor activity in #pretreated #pancreatic #cancer #ESMO24 ESMO - Eur. Oncology 🧬 Read more: buff.ly/3XGY2c3